{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:56Z","timestamp":1790913716271,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12288-024-01777-z","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:02:46Z","timestamp":1715580166000},"page":"564-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real World Outcomes with Treatment Free Remission in Chronic Myeloid Leukemia-Experience from a Tertiary Care Cancer Centre"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7223-7726","authenticated-orcid":false,"given":"Rup Jyoti","family":"Sarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhan","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Srikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmoy","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashwant","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Nandhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Kumar","family":"Bondili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Bonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashmukh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil Vijay","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papagudi","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Gujral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"issue":"10","key":"1777_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376(10):917\u2013927","journal-title":"N Engl J Med"},{"issue":"2","key":"1777_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P et al (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35(2):440\u2013453","journal-title":"Leukemia"},{"issue":"20","key":"1777_CR3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C et al (2016) Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J ClinOncol Off J Am SocClinOncol 34(20):2333\u20132340","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"issue":"24","key":"1777_CR4","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ et al (2019) Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med 381(24):2315\u20132326","journal-title":"N Engl J Med"},{"issue":"21","key":"1777_CR5","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C et al (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138(21):2042\u20132050","journal-title":"Blood"},{"issue":"24","key":"1777_CR6","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J ClinOncol Off J Am SocClinOncol 34(24):2851\u20132857","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"issue":"2","key":"1777_CR7","first-page":"71","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L (2016) Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. CurrHematolMalig Rep 11(2):71\u201379","journal-title":"CurrHematolMalig Rep"},{"issue":"1","key":"1777_CR8","doi-asserted-by":"publisher","first-page":"e2021004","DOI":"10.4084\/mjhid.2021.004","volume":"13","author":"N Gupta","year":"2021","unstructured":"Gupta N, Mahapatra M, Seth T, Tyagi S, Sazawal S, Saxena R (2021) Social and Financial Barriers to Optimum TKI Treatment in Patients with Chronic Myeloid Leukemia-A Knowledge-Attitudes-Practices Study from India. Mediterr J Hematol Infect Dis 13(1):e2021004","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"11","key":"1777_CR9","first-page":"204062072096612","volume":"31","author":"E Abruzzese","year":"2020","unstructured":"Abruzzese E, Mauro M, Apperley J, Chelysheva E (2020) Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. TherAdvHematol 31(11):2040620720966120","journal-title":"TherAdvHematol"},{"issue":"4","key":"1777_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bjh.15633","volume":"185","author":"HS Sabnis","year":"2019","unstructured":"Sabnis HS, Keenum C, Lewis RW, Patterson B, Bergsagel J, Effinger KE et al (2019) Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. Br J Haematol 185(4):795\u2013799","journal-title":"Br J Haematol"},{"issue":"4","key":"1777_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"23","key":"1777_CR12","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","volume":"5","author":"C Pavlovsky","year":"2021","unstructured":"Pavlovsky C, Abello Polo V, Pagnano K, Varela AI, Agudelo C, Bianchini M et al (2021) Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Adv 5(23):4855\u20134863","journal-title":"Blood Adv"},{"issue":"1","key":"1777_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128(1):17\u201323","journal-title":"Blood"},{"issue":"1","key":"1777_CR14","first-page":"433","volume":"2019","author":"H Malhotra","year":"2019","unstructured":"Malhotra H, Radich J, Garcia-Gonzalez P (2019) Meeting the needs of CML patients in resource-poor countries. Hematol Am SocHematolEduc Program 2019(1):433\u2013442","journal-title":"Hematol Am SocHematolEduc Program"},{"key":"1777_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"1","key":"1777_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/ijmr.ijmr_1090_21","volume":"157","author":"D Goni","year":"2023","unstructured":"Goni D, Jain A, Singh C, Jindal N, Nampoothiri R, Jandial A et al (2023) Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study. Indian J Med Res 157(1):87\u201391","journal-title":"Indian J Med Res"},{"issue":"3","key":"1777_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0971-5851.123711","volume":"34","author":"S Bansal","year":"2013","unstructured":"Bansal S, Prabhash K, Parikh P (2013) Chronic myeloid leukemia data from India. Indian J Med PaediatrOncolOff J Indian Soc Med PaediatrOncol 34(3):154\u2013158","journal-title":"Indian J Med PaediatrOncolOff J Indian Soc Med PaediatrOncol"},{"issue":"3","key":"1777_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al (2017) Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J ClinOncol Off J Am SocClinOncol 35(3):298\u2013305","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"key":"1777_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/BTT.S5775","volume":"4","author":"TI Mughal","year":"2010","unstructured":"Mughal TI, Schrieber A (2010) Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol Targets Ther 4:315\u2013323","journal-title":"Biol Targets Ther"},{"issue":"22","key":"1777_CR20","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zach\u00e9e P, Berneman Z et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401\u20135411","journal-title":"Blood"},{"issue":"1","key":"1777_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","volume":"94","author":"R Hehlmann","year":"2019","unstructured":"Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ et al (2019) Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol 94(1):46\u201354","journal-title":"Am J Hematol"},{"issue":"130","key":"1777_CR22","first-page":"1597","volume":"8","author":"DM Ross","year":"2017","unstructured":"Ross DM, Pagani IS, Shanmuganathan N, Seymour JF, Mills AK, Filshie RJ et al (2017) Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Blood 8(130):1597","journal-title":"Blood"},{"issue":"6","key":"1777_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19(6):747\u2013757","journal-title":"Lancet Oncol"},{"issue":"13","key":"1777_CR24","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","volume":"4","author":"P Rousselot","year":"2020","unstructured":"Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M (2020) Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv 4(13):3034\u20133040","journal-title":"Blood Adv"},{"issue":"8","key":"1777_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ajh.26556","volume":"97","author":"E Inzoli","year":"2022","unstructured":"Inzoli E, Aroldi A, Piazza R, Gambacorti-Passerini C (2022) Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. Am J Hematol 97(8):1075\u20131085","journal-title":"Am J Hematol"},{"issue":"18","key":"1777_CR26","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","volume":"119","author":"S Branford","year":"2012","unstructured":"Branford S, Yeung DT, Prime JA, Choi SY, Bang Hee J, Park JE et al (2012) BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 119(18):4264\u201371","journal-title":"Blood"},{"issue":"19","key":"1777_CR27","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2019004371","volume":"136","author":"E Diral","year":"2020","unstructured":"Diral E, Mori S, Antolini L, Abruzzese E, Le Coutre P, Martino B et al (2020) Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood 136(19):2237\u20132240","journal-title":"Blood"},{"issue":"11","key":"1777_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035","journal-title":"Lancet Oncol"},{"issue":"5","key":"1777_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","volume":"144","author":"DM Ross","year":"2018","unstructured":"Ross DM, Masszi T, G\u00f3mez Casares MT, Hellmann A, Stentoft J, Conneally E et al (2018) Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res ClinOncol 144(5):945\u2013954","journal-title":"J Cancer Res ClinOncol"},{"issue":"10","key":"1777_CR30","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90(10):910\u2013914","journal-title":"Am J Hematol"},{"issue":"Supplement_1","key":"1777_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2019-131500","volume":"134","author":"S Claudiani","year":"2019","unstructured":"Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J et al (2019) Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). Blood 134(Supplement_1):26\u201326","journal-title":"Blood"},{"issue":"11","key":"1777_CR32","doi-asserted-by":"publisher","first-page":"631570","DOI":"10.3389\/fonc.2021.631570","volume":"10","author":"M Breccia","year":"2021","unstructured":"Breccia M, Abruzzese E, Annunziata M, Luciano L, Sica S (2021) Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. Front Oncol 10(11):631570","journal-title":"Front Oncol"},{"issue":"1","key":"1777_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019000120","volume":"134","author":"N Shanmuganathan","year":"2019","unstructured":"Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM et al (2019) Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood 134(1):85\u201389","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01777-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T22:06:09Z","timestamp":1729980369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01777-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1777"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01777-z","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial or non financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}